IPCALAB

Ipca Laboratories Share Price

 

 

Invest in Ipca Laboratories with 3.29X leverage

Invest with MTF

Performance

  • Low
  • ₹1,456
  • High
  • ₹1,498
  • 52 Week Low
  • ₹1,168
  • 52 Week High
  • ₹1,595
  • Open Price₹1,493
  • Previous Close₹1,486
  • Volume47,636
  • 50 DMA₹1,444.05
  • 100 DMA₹1,418.90
  • 200 DMA₹1,407.78

Investment Returns

  • Over 1 Month + 3.4%
  • Over 3 Month + 15.3%
  • Over 6 Month -5.06%
  • Over 1 Year -3.5%

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 44.6
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 37,112
  • P/B Ratio
  • 5
  • Average True Range
  • 46.17
  • EPS
  • 39.02
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 20.26
  • RSI
  • 48.94
  • MFI
  • 59.84

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,462.80
-22.8 (-1.53%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹1,476.43
  • 50 Day
  • ₹1,444.05
  • 100 Day
  • ₹1,418.90
  • 200 Day
  • ₹1,407.78

Resistance and Support

1472.1 Pivot Speed
  • R3 1,529.70
  • R2 1,513.60
  • R1 1,488.20
  • S1 1,446.70
  • S2 1,430.60
  • S3 1,405.20

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies.

Ipca Laboratories has an operating revenue of Rs. 9,357.41 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 13% is healthy, ROE of 10% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 6% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 15% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-11 Quarterly Results
2025-05-29 Audited Results & Final Dividend
2025-02-13 Quarterly Results
Date Purpose Remarks
2025-08-05 FINAL Rs.2.00 per share(200%)Final Dividend
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
View Ipca Laboratories Dividend History Arrow
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

44.72%
30.52%
6.15%
10.62%
0%
5.88%
2.11%

About Ipca Laboratories

  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director & CFO
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,462 As on 26 January, 2026 | 01:33

The Market Cap of Ipca Laboratories is ₹37111.9 Cr As on 26 January, 2026 | 01:33

The P/E ratio of Ipca Laboratories is 44.6 As on 26 January, 2026 | 01:33

The PB ratio of Ipca Laboratories is 5 As on 26 January, 2026 | 01:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23